Application of coenzyme Q10 in combination therapy of arterial hypertension

Kardiologiya

Volumn 51, Issue 6, 2011, Pages 26-31

  Mikhin, V P ^a   Kharchenko, A V ^a   Roslyakova, E A ^a   Chernyatina, M A ^a  

^a KURSK STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Arierial hypertension; Coenzyme Q10 enalapril; Cyioprofection

Indexed keywords

ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; ENALAPRIL; ENDOTHELIUM DERIVED RELAXING FACTOR; UBIDECARENONE; UBIQUINONE; VITAMIN;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG MONITORING; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG MONITORING; DRUG THERAPY, COMBINATION; ENALAPRIL; ENDOTHELIUM, VASCULAR; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; UBIQUINONE; VASODILATION; VITAMINS;

EID: 80054095072     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chobanian A. V., Bakris G. L., Black H. R. et al. Seventh report of the joint nationat committee on prevention, detection, evatuation, and treatment of high btood pressure. J Hypertens 2003;42:1206-1232.
2. The Task Force for the management of arteriat hypertension of the European Society of Hypertension and of the European Society of Cardiotogy. Guidetines for the management of arteriat hypertension. J Hypertens 2007;25:1105-1187.
3. 10 in patients with acute myocardial infarction. Adv Exp Med Biol 2003;526:41-48.
4. 10 and antioxidants in acute myocardial infarction. Mol Aspects Med 1994;15:143-147.
5. 10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J 2007;28:2249-2255.
6. 10 in isolated systolic hypertension. Southern Med J 2002;94:1112-1117.
7. 10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 2007;21:297-306.
8. 10 in essential hypertension. Curr Ther Res 1992;51:668-672.
9. 10 on essential arterial hypertension. Curr Ther Res 1990;47:841-845.
10. Celermajer D. S., Sorensen K. E., Gooch V. M. et al. Non-invasive detection of endothetial dysfunction in chitdren and adults at risk of atherosclerosis. Lancet 1992;340:111-1115.
11. Pepine C. J., Celermajer D. S., Drexler H. Vascutar heatth as a therapeutic tagert in cardiovascular disease. University of Florida 1998.
12. Michel J.-B. NO (Nitric oxide) and Cardiovascular Homeostasis. Menarinilnternationa) industrie Farmaceutiche Riunite s.r.t. Paris: Panza 1999.
13. Van Zwieten P. A. Endothetial dysfunction in hypertension. A critical evaluation. Biood Press 1997;2:67-70.
14. Shimokawa H. Endothetial dysfunction in hypertension. J Atheroscter Thromb 1998;4:118-127.
15. Noll G., Tschudi M., Nava E., Luscher T. F. Endothelium and high Mood pressure. Int J Microcirc Ciin Exp 1997;17:273-279.
16. Vanhoutte P. M., Boulanger C. M. Endotheiium-dependent responses in hypertension. Hypertens Res 1995;18:87-98.
17. Panza J. A. Endothelial dysfunction in essentiat hypertension. Ciin Cardiol 1997; (11 Suppl 2): 26-33.
18. Panza J. A., Casino P. R., Kilcoyne C. M., Quyyumi A. A. Rote of endotheiium-derived nitric oxide in the abnorma] endotheiium-dependent vascutar reiaxation of patients with essential hypertension. Circutation 1993;87:1468-1474.